Summary | Investors should play it safe when it comes to
Chinese drug makers as the sector is going through a major
transition despite buoyant stock prices and positive net profit
growth last year, an analyst from US broker Jefferies has
warned....
Chinese drug makers as the sector is going through a major
transition despite buoyant stock prices and positive net profit
growth last year, an analyst from US broker Jefferies has
warned....
scmp.com | 14 May 2017